达拉帕地产品是Darapladib (SB-480848), is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor (IC₅₀ of 0.25 nM). It produces sustained inhibition of plasma Lp-PLA2 activity in humans receiving intensive atorvastatin therapy. Lp-PLA2 inhibition with Darapladib also reduces the development of coronary atherosclerotic plaques.